文献速递血液净化与透析

可溶性TLR2靶向阻断TLR-DAMP通路预防腹膜透析液诱导的腹膜纤维化

Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solution-induced fibrosis.
PubMed 文献 · Kidney Int · 2018-05-31

本研究探讨Toll样受体(TLR)及损伤相关分子模式(DAMP)在腹膜透析液(PDS)诱导的腹膜纤维化中的作用及靶向治疗潜力。多种PDS可刺激人腹膜白细胞、间皮细胞及小鼠腹膜白细胞产生促炎和促纤维化反应,TLR2/4阻断或基因敲除可抑制这些效应。PDS通过增加Hsp70和透明质酸释放间接激活TLR2/4,可溶性TLR2在小鼠体内可预防PDS诱导的腹膜纤维化并调节免疫细胞比例,提示靶向TLR-DAMP策略具有治疗潜力。

要点

  • PDS通过释放Hsp70和透明质酸等DAMP间接激活TLR2/4促腹膜炎症。
  • 阻断或敲除TLR2/4可抑制PDS诱导的促炎和促纤维化反应。
  • 可溶性TLR2在小鼠体内预防PDS诱导的腹膜纤维化并恢复Treg水平。

核心结论

  • TLR2/4、Hsp70和透明质酸在PDS诱导的腹膜炎症和纤维化中起主要作用。
  • 靶向TLR-DAMP策略具有预防PDS诱导腹膜纤维化的治疗潜力。

研究设计与样本

  • 研究评估了TLR和DAMP在PDS诱导纤维化模型中的作用及TLR-DAMP靶向的治疗潜力。
  • 体外使用PD患者腹膜白细胞、间皮细胞及小鼠腹膜白细胞;体内小鼠每日导管输注PDS建立腹膜纤维化模型。

主要发现

  • 多种PDS可刺激人和小鼠腹膜细胞产生促炎和促纤维化反应,TLR2/4阻断或敲除可抑制这些效应。
  • PDS不诱导快速ERK磷酸化或IκB-α降解,提示不含直接激活TLR的成分。
  • PDS增加人和小鼠腹膜细胞释放Hsp70和透明质酸(均为TLR2/4的DAMP配体),阻断二者可减少PDS驱动的炎症。
  • 可溶性TLR2在体外减少PDS诱导的促炎和促纤维化细胞因子释放。
  • 小鼠每日导管输注PDS导致腹膜纤维化,联合给予可溶性TLR2可预防纤维化、抑制促纤维化基因表达和促炎细胞因子产生、减少白细胞/中性粒细胞募集、恢复Treg细胞水平并提高Treg:Th17比值。

临床怎么用

  • 可溶性TLR2或TLR2/4阻断可能作为预防腹膜透析相关腹膜纤维化的潜在策略。
  • Hsp70和透明质酸等DAMP可作为监测PDS诱导腹膜炎症的潜在生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peritoneal membrane failure due to fibrosis limits the use of peritoneal dialysis (PD). Peritoneal fibrosis may potentially be induced by sterile inflammation caused by ongoing cellular stress due to prolonged exposure to PD solutions (PDS). Effective therapies to prevent this process remain to be developed. Toll-like receptors (TLRs) mediate sterile inflammation by recognizing damage-associated molecular patterns (DAMPs) released by cellular stress. We evaluated the involvement of TLRs and DAMPs in PDS-induced fibrosis models and the therapeutic potential of TLR-DAMP targeting for preventing fibrosis. A range of PDS elicited pro-inflammatory and fibrotic responses from PD patient peritoneal leukocytes, mesothelial cells and mouse peritoneal leukocytes. TLR2/4 blockade of human peritoneal cells or TLR2/4 knockouts inhibited these effects. PDS did not induce rapid ERK phosphorylation or IκB-α degradation, suggesting that they do not contain components capable of direct TLR activation. However, PDS increased the release of Hsp70 and hyaluronan, both TLR2/4 DAMP ligands, by human and mouse peritoneal cells, and their blockade decreased PDS-driven inflammation. Soluble TLR2, a TLR inhibitor, reduced PDS-induced pro-inflammatory and fibrotic cytokine release ex vivo. Daily catheter infusion of PDS in mice caused peritoneal fibrosis, but co-administration of soluble TLR2 prevented fibrosis, suppressed pro-fibrotic gene expression and pro-inflammatory cytokine production, reduced leukocyte/neutrophil recruitment, recovered Treg cell levels and increased the Treg:Th17 ratio. Thus, TLR2/4, Hsp70 and hyaluronan showed major roles in PDS-induced peritoneal inflammation and fibrosis. The study demonstrates the therapeutic potential of a TLR-DAMP targeting strategy to prevent PDS-induced fibrosis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Raby AC, González-Mateo GT, Williams A, et al. Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solution-induced fibrosis. Kidney Int. 2018. PMID: 29861057. doi:10.1016/j.kint.2018.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。